

---

# INAUGURAL EATRIS CONFERENCE

---



3<sup>RD</sup> AND 4<sup>TH</sup> JUNE 2013  
AMSTERDAM, THE NETHERLANDS

---

---

# WELCOME

---

Dear Colleagues and Guests,

On behalf of my co-director Frank de Man, and the whole team at EATRIS, I am honoured to welcome you to this meeting, celebrating the inauguration of operations for EATRIS. This is an important milestone for EATRIS, as we move forward following a lengthy construction process and are now free to focus on adding value in the scientific and healthcare arena.

As you know, the complexity of translational medicine and innovation is increasing. Efficient access to the broad array of advanced technologies and know-how in the field is becoming increasingly difficult for a single institution. Our distributed infrastructure is young and growing but already has the capacity to serve the needs of our stakeholders through the provision of an extensive range of translational research services and expertise for high potential projects.

We feel that this initiative is a crucial step forward for the European Union. It allows Member States to avoid infrastructure duplications, and facilitates more efficient use of the available resources in these scientifically and economically challenging times.

However, EATRIS is not only a service provider but is also a team of scientists who aim to improve outcomes in translational medicine and to challenge the current paradigms of therapeutic and diagnostic development. Science is also a social endeavour and as scientists it is our responsibility to serve present and future generations to the best of our ability. In the end we, like yourselves, are committed to finding solutions to some of the primary societal challenges of our time.

An exciting number of issues are on our agenda for discussion during this meeting. We wish to provide you with an informative and stimulating event. And finally we hope that, with your involvement, EATRIS will become a valuable partner in facilitating and energizing translational research in Europe, and ultimately bringing substantial benefit to patients the world over. Together we can achieve this.

Giovanni Migliaccio,  
Scientific Director, EATRIS

---

---

MONDAY 3<sup>RD</sup> JUNE 2013  
**PROGRAMME**

---

---

**12:30 – 13:25**

**The current translational research landscape**

---

- 11:30 – 12:30 Registration and lunch
- 12:30 – 12:45 Welcome  
*Giovanni Migliaccio, Ph.D. Amsterdam, The Netherlands*
- 12:45 – 13:05 Translational research concepts  
— the need to close the gap  
*Giovanni Migliaccio, Ph.D. Amsterdam, The Netherlands*
- 13:05 – 13:25 Goal-directed collaboration: How EATRIS works  
*Anton Ussi, M.Sc. Amsterdam, The Netherlands*
- 

**13:25 – 16:00**

**Serving Europe's needs in translational research  
and alleviating the bottlenecks**

---

- 13:25 – 13:45 Translational Medicine and Advanced Therapy  
Medicinal Products  
*Maria Cristina Galli, Ph.D. Rome, Italy*
- 13:45 – 14:05 Translational Medicine and Biomarkers  
*Olli Kallioniemi, MD. Ph.D. Helsinki, Finland*
- 14:05 – 14:25 Translational Medicine and Imaging and Tracing  
*Guus van Dongen, Ph.D. Amsterdam, The Netherlands*
-

---

## MONDAY 3<sup>RD</sup> JUNE 2013

---

- 14:25 – 14:45 Break
- 14:45 – 15:05 Translational Medicine and Small Molecules  
*Mario Salmona, Ph.D. Milan, Italy*
- 15:05 – 15:25 Vaccine development: From bench to clinic  
*Jan Langermans, Ph.D. Wageningen, The Netherlands*
- 

### **15:25 – 20:00** **Networking events**

---

- 15:25 – 16:30 Round table discussion: Optimising the  
yield of academic research  
*Marcel Levi, MD. Ph.D. Amsterdam, The Netherlands*
- 16:30 – 17:00 The EATRIS umbrella and support function  
*Frank de Man, LL.M. Ph.D. Amsterdam, The Netherlands*
- 17:00 – 19:00 Icebreaker session
- 19:00 – 20:00 Walking dinner, meet and eat
-

---

MONDAY 3<sup>RD</sup> JUNE 2013

# FACULTY

---



● GUUS VAN DONGEN, Ph.D.

VU University Medical Center, The Netherlands

Guus van Dongen is Professor and Head of Preclinical Imaging at the Department of Radiology and Nuclear Medicine (Tracer Center Amsterdam), and project leader of the Imaging Center Amsterdam, Vumc, The Netherlands. He is also the Chair of the Imaging and Tracing Product Platform at EATRIS. He has a wealth of experience in molecular targeted therapy and is known for his work in “immuno-PET” and “TKI-PET”, which utilises PET imaging of radiolabeled mAbs and TKIs, and also for his research in photoimmunodetection.

---



● MARIA CRISTINA GALLI, Ph.D.

ISS, Italy

Maria Cristina Galli is Senior Researcher at the Istituto Superiore di Sanità (ISS), Italy. Dr Galli is the co-Chair of the ATMP Product Platform within EATRIS and, as a quality assessor and regulatory expert for biotechnology and gene therapy in the Committee for Advanced Therapies (CAT) and Gene Therapy Working Party, brings a wealth of knowledge in the development of new technologies in this field.

---



● OLLI KALLIONIEMI, MD. Ph.D.

FIMM, Finland

Olli Kallioniemi is Director of the Institute for Molecular Medicine (FIMM), Finland and is Chair of the Biomarkers Product Platform within EATRIS. He is author of over 300 publications, inventor and co-inventor of 20 issued patents, with a focus on diagnostic technology development and bioinformatics – he has a special interest in the use of translational research to improve diagnostics and therapy of leukemia.

---

---

## MONDAY 3<sup>RD</sup> JUNE 2013

---



● JAN LANGERMANS, Ph.D.  
BPRC, The Netherlands

Jan Langermans is Chairman of the Animal Science Department of BPCR, The Netherlands and the Chair for the Vaccines Product Platform at EATRIS. He is an expert in vaccine development, animal studies, ethics and biosafety.

---



● MARCEL LEVI, MD, Ph.D.

University of Amsterdam, The Netherlands

Marcel Levi is Professor of Medicine at the University of Amsterdam and Dean of the Faculty of Medicine of the University of Amsterdam. He has published more than 700 articles in international scientific journals and brings a multidisciplinary approach to the table through his professional career as a doctor, governor, teacher and scientist.

---



● FRANK DE MAN, LL.M. Ph.D.  
Finance Director EATRIS

Frank de Man is Finance Director of EATRIS and has extensive experience in the setting up and financing of public-private initiatives in research and healthcare.

---



● GIOVANNI MIGLIACCIO, Ph.D.  
Scientific Director EATRIS

Giovanni Migliaccio is Scientific Director of EATRIS and an expert in the area of Cell and Gene Therapies for the European Medicines Agency (EMA) and the European Department for Quality of Medicines (EDQM).

---

---

## MONDAY 3<sup>RD</sup> JUNE 2013

---



● MARIO SALMONA, Ph.D.

Mario Negri Institute, Italy

Mario Salmona is Professor and Head of the Department of Molecular Biochemistry and Pharmacology and Head of Laboratory of Biochemistry and Protein Chemistry of The Mario Negri Institute, Italy. He is also Chair of the Small Molecules Product Platform at EATRIS. He is an expert in the field of the structural and functional studies of specific pharmacologically important gene products using the latest animal and computer simulated methods to review protein misfolding and neurodegeneration.



● ANTON USSI, M.SC.

Head of Operations EATRIS

Anton Ussi is a specialist in the establishment and execution of strategic public-private and public-public collaborations based on the deployment of high value translational research infrastructure for medicine.

---

---

TUESDAY 4<sup>TH</sup> JUNE 2013  
**PROGRAMME**

---

---

**09:00 – 10:50**

**Welcome and introduction**

---

- 09:00 – 10:00 Registration
- 10:00 – 10:10 Welcome  
*Marja-Liisa Niemi, Helsinki, Finland*
- 10:10 – 10:30 An introduction to EATRIS and its members  
*Giovanni Migliaccio, Ph.D. Amsterdam, The Netherlands*
- 10:30 – 10:50 Greater than the sum: making international collaboration in translational medicine work  
*Anton Ussi, M.Sc. Amsterdam, The Netherlands*
- 

**10:50 – 13:00**

**A review of current translational research models  
from a global perspective**

---

- 10:50 – 11:15 The Czech Republic vision on biomedical research cooperation  
*Miroslava Kopicova, Prague, Czech Republic*
- 11:15 – 11:40 Public-private partnerships and rare diseases  
*Speaker to be confirmed*
- 11:40 – 12:05 Case study — making it happen the 'down under' way  
*Stewart Hay, Ph.D. Melbourne, Australia*
-



---

## TUESDAY 4<sup>TH</sup> JUNE 2013

---

12:05 – 12:25 Case study – where East meets West  
*Akihiro Shimosaka, Ph.D. Tokyo, Japan*

12:25 – 12:55 A review and panel discussion  
*Moderator to be confirmed*

---

### **12:55 – 14:00** **Networking events**

---

12:55 – 13:00 Official launch of EATRIS  
*Wim Stalman, MD. Ph.D. Amsterdam, The Netherlands*

13:00 – 14:00 Lunch

---

### **14:00 – 16:00** **Exploring opportunities to close the translational research gap**

---

14:00 – 14:20 The opportunities within industry – filling the gap  
*Gerd Schnorrenberg, Prof. Ph.D.*  
*Biberach an der Riß, Germany*

14:20 – 14:40 The key to successful patient participation  
*Buddug Cope, M.Sc. Cambridge, UK*

14:40 – 15:10 The biotech SME as a risk mediator in translational research  
*Tom Saylor, MBA Cambridge, UK*

---

---

## TUESDAY 4<sup>TH</sup> JUNE 2013

---

- 15:10 – 15:30 The charity perspective on translational research  
*Gerrit Meijer, MD. Ph.D. /  
Wia Timmerman, Ph.D. Amsterdam, The Netherlands*
- 15:30 – 15:50 A review and panel discussion  
*Joan Comella, Ph.D. Barcelona, Spain*
- 15:50 – 16:00 Summary and closing remarks  
*Maria Ferrantini, Ph.d. Rome, Italy*
- 16:00 Close
-

---

## TUESDAY 4<sup>TH</sup> JUNE 2013

# FACULTY

---



- JOAN X. COMELLA, MD. Ph.D.  
University of Barcelona, Spain

Joan X. Comella is Professor of Cell Biology at the University of Barcelona (UAB). He leads the Spanish scientific participation in EATRIS and manages the relationship of this consortium with the ISCIII and the Spanish Ministry of Science and Innovation. Joan Comella is also the Chair of the Board of National Directors of EATRIS.

---



- BUDDUG COPE  
Genetic Alliance, M.Sc. UK

Buddug Cope is Director of Development at Genetic Alliance UK — the national alliance of 160 patient groups, representing all those affected by genetic conditions. Genetic Alliance UK supports the acceleration of scientific and medical innovation into healthcare, improving and developing health services that deliver better patient outcomes and address unmet health need through coordinated care, support and access to medicines. Genetic Alliance UK runs the multistakeholder campaign group Rare Disease UK, which campaigns for improved healthcare and research for the 7,000 rare diseases that affect 3.5million people in the UK.

---



- STEWART HAY, Ph.D.  
Therapeutic Innovation Australia, Australia

Stewart Hay is the CEO of Therapeutic Innovation Australia (TIA) which supports translational health researchers through providing world class commercial expertise and enabling access to state of the art equipment and facilities. Stewart will share some valuable insights on TIAs strategy to improve the efficiency and effectiveness of translational health research in Australia through local development of small molecule, biological, pre-clinical and clinical trial capabilities.

---

---

## TUESDAY 4<sup>TH</sup> JUNE 2013

---



● GERRIT MEIJER, MD. Ph.D.

VU University Medical Center, The Netherlands

Gerrit Meijer is a Professor in pathology who leads a translational research group that focuses on gastrointestinal cancer. This involves -omics based tumour profiling, using DNA, RNA and proteomics based techniques, in order to stratify patient groups and arrive at individual tailored therapies. Furthermore, genomic and proteomics profiling of pre-malignant lesions is used for biomarker development to improve (colorectal) cancer screening. Building infrastructure to support this translational research is another focus.

---



● MARJA-LIISA NIEMI, Lic.Phil.

Ministry of Education, Finland

Marja-Liisa Niemi is responsible for strategic research policy development in the areas of health research and innovations (e.g. national policies, international collaboration, infrastructures, financing) in Finland. She represents the Finnish Government in the preparation of the ERIC applications of EATRIS, BBMRI and the International Consortium Agreement for ELIXIR as well as the preparation of GmbH for Infrafrontier. She is a delegate to ESFRI Health and Food Strategic Working Group. She chairs the EATRIS Board of Governors.

---



● THOMAS REESE SAYLOR, MBA.

Arecor Ltd. UK

Tom Saylor is an experienced CEO with a track record of building and managing entrepreneurial organizations. His experience includes fundraising, strategy development, in- and out-licensing, and acquisitions in Asia, Europe and the United States and can provide a truly global outlook on the issues faced when bridging the translational research gap.

---

---

## TUESDAY 4<sup>TH</sup> JUNE 2013

---



- GERD SCHNORRENBERG, Prof. Ph.D.  
Senior Vice president, Boehringer Ingelheim  
Pharma GmbH & Co

Gerd Schnorrenberg is honorary Professor of the federal state Rheinland-Pfalz in parallel with his function at Boehringer Ingelheim. He has broad experience in drug discovery and development

and manages one of the biggest research campuses within Boehringer Ingelheim, with research on cardiometabolic diseases, CNS diseases, and respiratory diseases.

---




- AKIHIRO SHIMOSAKA, Ph.D.  
Director Research Foundation, Japan

Akihiro Shimosaka is Director at the Research Foundation for Community Medicine in Tokyo and serves as Chairman of the ISCT regulatory affairs for Asian-Pacific region. He has worked on research projects for Amgen, Genentech,

Immunex, Dendreon, Anosys, Cerus, Miltenyi, Medarex etc. and is an expert in the field of oncology, haematology and immunology.

---



- WIM STALMAN, MD. Ph.D.  
Dean Medical Faculty, VU University  
Medical Center, The Netherlands

Wim Stalman is Professor of General Practice at the Institute for Research in Extramural Medicine (EMGO) at the VU University Medical Center in Amsterdam and Vice President of the board of directors of the VU University Medical Center and Dean of the medical faculty.

---

---

## TUESDAY 4<sup>TH</sup> JUNE 2013

---



● WIA TIMMERMAN, Ph.D.

Dutch Cancer Society, The Netherlands

Dr. Wia Timmerman is Project Leader at the Dutch Cancer Society with the remit to pursue innovation in the field of Translational Research. She is a medical biologist and has many years experience working within a Clinical Research Organisation for Phase I and Phase IIa studies.

Wia Timmerman will share the current advances of translational research at the Dutch Cancer Society.

---

---

### Scope of the meeting

- To discuss challenges and opportunities to bridge the innovation gap and reduce overall cost in global therapeutic and diagnostic innovation;
- To hear from international stakeholders on their needs and discuss how to jointly approach the challenges in translational medicine;
- To celebrate the inauguration of EATRIS operations as a new international organization.

### Educational Objectives

At the end of the EATRIS conference participants will :

1. Be up to date on the current international cooperation models of translational research.
2. Gain insights into the current challenges and future perspectives of academic translational research. Be informed on the current state of the art in ATMP, biomarkers, imaging and tracing, small molecules and vaccines.
3. Understand how novel public-private collaborative research models can advance translational research.
4. Know how and where to access EATRIS translational research services.

### Target Audience

- Researchers from EATRIS institutions
- Researchers in translational medicine
- Delegates from Pharmaceutical industry
- SMEs
- Charities
- Research funding organisations
- Government bodies, such as regulatory authorities
- Patients' organizations

### Financial support acknowledgement

EATRIS would like to thank the participating member states represented in the Board of Governors: Czech Republic, Denmark, Estonia, Finland, France, Germany, Italy, The Netherlands, Norway, Spain.



[WWW.EATRIS.EU](http://WWW.EATRIS.EU)

---